BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 11745893)

  • 1. Outcome of high-risk neuroblastoma using a dose intensity approach: improvement in initial but not in long-term results.
    Castel V; Cañete A; Navarro S; García-Miguel P; Melero C; Acha T; Navajas A; Badal MD
    Med Pediatr Oncol; 2001 Dec; 37(6):537-42. PubMed ID: 11745893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification.
    Kaneko M; Tsuchida Y; Mugishima H; Ohnuma N; Yamamoto K; Kawa K; Iwafuchi M; Sawada T; Suita S
    J Pediatr Hematol Oncol; 2002 Nov; 24(8):613-21. PubMed ID: 12439032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of induction chemotherapy in children older than 18 months with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7).
    Mora J; Cruz O; Lavarino C; Rios J; Vancells M; Parareda A; Salvador H; Suñol M; Carrasco R; Guillen A; Mañé S; de Torres C
    Clin Transl Oncol; 2015 Jul; 17(7):521-9. PubMed ID: 25596034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy.
    Valteau-Couanet D; Le Deley MC; Bergeron C; Ducassou S; Michon J; Rubie H; Le Teuff G; Coze C; Plantaz D; Sirvent N; Bouzy J; Chastagner P; Hartmann O
    Pediatr Blood Cancer; 2014 Jun; 61(6):977-81. PubMed ID: 23970413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comprehensive protocol for diagnosis and treatment of childhood neuroblastoma--results of 45 cases].
    Tang JY; Pan C; Chen J; Xu M; Chen J; Xue HL; Gu LJ; Dong R; Ye H; Zhou M; Wang YP
    Zhonghua Er Ke Za Zhi; 2006 Oct; 44(10):770-3. PubMed ID: 17229383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy.
    Bagatell R; Rumcheva P; London WB; Cohn SL; Look AT; Brodeur GM; Frantz C; Joshi V; Thorner P; Rao PV; Castleberry R; Bowman LC
    J Clin Oncol; 2005 Dec; 23(34):8819-27. PubMed ID: 16314642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of surgery in stage IV neuroblastoma.
    Castel V; Tovar JA; Costa E; Cuadros J; Ruiz A; Rollan V; Ruiz-Jimenez JI; Perez-Hernández R; Cañete A
    J Pediatr Surg; 2002 Nov; 37(11):1574-8. PubMed ID: 12407542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial.
    Pearson AD; Pinkerton CR; Lewis IJ; Imeson J; Ellershaw C; Machin D; ;
    Lancet Oncol; 2008 Mar; 9(3):247-56. PubMed ID: 18308250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Localized unresectable neuroblastoma: results of treatment based on clinical prognostic factors.
    Garaventa A; Boni L; Lo Piccolo MS; Tonini GP; Gambini C; Mancini A; Tonegatti L; Carli M; di Montezemolo LC; Di Cataldo A; Casale F; Mazzocco K; Cecchetto G; Rizzo A; Bernardi B;
    Ann Oncol; 2002 Jun; 13(6):956-64. PubMed ID: 12123342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Percentage tumor necrosis following chemotherapy in neuroblastoma correlates with MYCN status but not survival.
    Bomken S; Davies B; Chong L; Cole M; Wood KM; McDermott M; Tweddle DA
    Pediatr Hematol Oncol; 2011 Mar; 28(2):106-14. PubMed ID: 21214410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved survival of children with advanced neuroblastoma treated by intensified therapy including myeloablative chemotherapy with stem cell transplantation: a retrospective analysis from the Tohoku Neuroblastoma Study Group.
    Imaizumi M; Watanabe A; Kikuta A; Takano T; Ito E; Shimizu T; Tsuchiya S; Iinuma K; Konno T; Ohi R; Hayashi Y;
    Tohoku J Exp Med; 2001 Oct; 195(2):73-83. PubMed ID: 11846211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term survivors of advanced neuroblastoma with MYCN amplification: A report of 19 patients surviving disease-free for more than 66 months.
    Kawa K; Ohnuma N; Kaneko M; Yamamoto K; Etoh T; Mugishima H; Ohhira M; Yokoyama J; Bessho F; Honna T; Yoshizawa J; Nakada K; Iwafuchi M; Nozaki T; Mimaya J; Sawada T; Nakamura T; Miyata H; Yamato K; Tsuchida Y
    J Clin Oncol; 1999 Oct; 17(10):3216-20. PubMed ID: 10506621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era.
    Kushner BH; Modak S; Kramer K; LaQuaglia MP; Yataghene K; Basu EM; Roberts SS; Cheung NK
    Cancer; 2014 Jul; 120(13):2050-9. PubMed ID: 24691684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unresectable localized neuroblastoma: improved survival after primary chemotherapy including carboplatin-etoposide. Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique (SFOP).
    Rubie H; Michon J; Plantaz D; Peyroulet MC; Coze C; Frappaz D; Chastagner P; Baranzelli MC; Méchinaud F; Boutard P; Lutz P; Perel Y; Leverger G; de Lumley L; Millot F; Stéphan JL; Margueritte G; Hartmann O
    Br J Cancer; 1998 Jun; 77(12):2310-7. PubMed ID: 9649151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1.
    Rubie H; De Bernardi B; Gerrard M; Canete A; Ladenstein R; Couturier J; Ambros P; Munzer C; Pearson AD; Garaventa A; Brock P; Castel V; Valteau-Couanet D; Holmes K; Di Cataldo A; Brichard B; Mosseri V; Marquez C; Plantaz D; Boni L; Michon J
    J Clin Oncol; 2011 Feb; 29(4):449-55. PubMed ID: 21172879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Localised and unresectable neuroblastoma in infants: excellent outcome with primary chemotherapy. Neuroblastoma Study Group, Société Française d'Oncologie Pédiatrique.
    Rubie H; Plantaz D; Coze C; Michon J; Frappaz D; Baranzelli MC; Chastagner P; Peyroulet MC; Hartmann O;
    Med Pediatr Oncol; 2001 Jan; 36(1):247-50. PubMed ID: 11464897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experience of the Izmir Pediatric Oncology Group on Neuroblastoma: IPOG-NBL-92 Protocol.
    Olgun N; Kansoy S; Aksoylar S; Cetingul N; Vergin C; Oniz H; Sarialioglu F; Kantar M; Uysal K; Tuncyurek M; Kargi A; Aktas S; Bayol U; Karaca I; Arikan A; Balik E; Aktug T; Elmas N; Kovanlikaya A; Kinay M; Anacak Y; Degirmenci B; Burak Z
    Pediatr Hematol Oncol; 2003; 20(3):211-8. PubMed ID: 12637217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melphalan combined with a carboplatin dose based on glomerular filtration rate followed by autologous stem cell rescue for children with solid tumours.
    Shaw PJ; Pinkerton CR; Yaniv I
    Bone Marrow Transplant; 1996 Dec; 18(6):1043-7. PubMed ID: 8971371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
    Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK
    J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial.
    Berthold F; Boos J; Burdach S; Erttmann R; Henze G; Hermann J; Klingebiel T; Kremens B; Schilling FH; Schrappe M; Simon T; Hero B
    Lancet Oncol; 2005 Sep; 6(9):649-58. PubMed ID: 16129365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.